Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
Zoetis (ZTS) Success Could Trigger Animal Healthcare Spin-Off Bonanza
-
Zoetis (ZTS) Closes 86.1M IPO; Pfizer (PFE) Remains 80% Owner
-
Pfizer's Zoetis (ZTS) Sees IPO Price of $22 - $25/Share
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
Q4 Preview: Analysts Cautious on Alcoa (AA) on Prices, Europe; Investors Gear for Upside
-
Deutsche Bank Downgrades ICON plc (ICLR) to Hold; Limited Near-Term EPS Visibility
-
Alcoa (AA) to Start Q3 Earnings Season; Declining Aluminum Prices May Weigh
-
Q2 Preview: Divide and Conquer May Not Be Pfizer's (PFE) Best Option; Pipeline Looks Strong
-
Pfizer (PFE) volatility flat at 23 into positive blood thinner clinical results
-
Notable Analyst Rating Changes 02/02: GCA, HLX, MTW, PFE Upgraded; ENTR, FMER, ATVI, PEP Downgraded
-
Pfizer (PFE) Is the Drug Wall Street Wants, Shares Jump 6%
-
Notable 52-Week Highs and Lows of the Day 02/01: PFE, MTW, CHK, BIDU High; OREX, TLB Low
-
Alcoa (AA) Looks To Kick Off Q410 Earnings Season On the Right Foot
-
Q3 Preview: Pfizer (PFE) Chugging Strong Into Earnings; M&A and Pipeline Key Focal Points (MRK, NVS)
-
Q3 Preview: Merck (MRK) Trading Strong Into Earnings, Looks to Nearly Double-Up Revs Y/Y (PFE, GSK, SNY)
-
Deutsche Bank Cuts Price Target on Pfizer (PFE) to $20; Maintains Buy
-
Notable Analyst Rating Changes 12/16: CNQ, SCHW, RCL, CCL, NLY, GLW, BFS, ADBE Upgraded; AYE, FE, EIX, STLD Downgraded
-
Notable Analyst Rating Changes 10/16: GOOG, LYG, KR, HOG, NTRI, AUDC upgrade; NOK, KMP, WSM, SHAW, NFLX Downgrade
-
Notable Analyst Rating Changes 8/17: WMT, BBT, IT, AN, N Upgraded; BJ, UBET, PSA Downgraded
-
David Moenning’s Daily State of the Markets: 7/22
-
Morning Movers 5/18: KONA, AHR, IDMI, LGTY, IBN, HEB Higher; SPIR, COIN, BIDZ, AYE Lower
-
Pfizer (PFE) calls active for second day in row as shares trend higher
-
David Moenning's Daily State of the Markets: 4/28
-
Trading Radar for 4/28: Bristol-Myers Squibb (BMY), Pfizer (PFE), BP (BP), Sun Micro (JAVA), Deutsche Bank (DB), E*TRADE (ETFC), Level 3 (LVLT) Report; Consumer Confidence Due
-
Morning Movers 3/12: CV Therapeutics (CVTX) Surges On Buyout, GE (GE) Up On Rating Cut/Stable Outlook
-
David Moenning's Daily State of the Markets: 2/2
-
Deutsche Bank Said Don't Pin Your Hopes On a AstraZeneca (AZN) Takeover Following PFE/WYE Deal
-
Wyeth (WYE) Jumps on Pfizer (PFE) Bid Talk
-
Notable Analyst Rating Changes 1/12: CFR, PALM, PFE Upgraded; AA, HOG, MDAS, BNI Downgraded
-
David Moenning's Daily State of the Markets: 10/20
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
Pre-Open Movers 9/3: Medivation (MDVN) Surges On Pfizer Deal; Corning (GLW) Sinks on Warning
-
David Moenning's Daily State of the Markets: 7/23
-
Pfizer's (PFE) Cash Flows Support Dividend -Deutsche Bank
-
David Moenning's Daily State of the Markets: 4/17
-
David Moenning's Daily State of the Markets: 1/23
-
Pre-Open Movers: Motorola (MOT) and Apple (APPL) Lower on Disappointing Guidance
